Compared to sporadic tumors, both BRCA1-mutated and BRCA2-mutated tumors show a higher Tumor Mutational Burden (TMB), calculated as the number of nonsynonymous mutations per Mb of coding sequence (Fig. 1b; Wilcoxon test, p = 9.9 × 10− 10 for BRCA1-mutated vs. sporadic tumors, p = 5.1 × 10− 8 for BRCA2-mutated vs. sporadic tumors). Here, BRCA1 is linked to neoplasm.